ECE2022 Poster Presentations Thyroid (136 abstracts)
Results of radioiodine remnant ablation with 30 mci dose in low-risk differentiated thyroid carcinoma (dtc)
Irene De Lara-Rodriguez 1 , Suset Dueñas Disotuar 1 , Ana R. Romero Lluch 1 , Juan Luis Tirado-Hospital 2 , Ana Piñar Gutiérrez 1 & Elena Navarro 1
1Virgen del Rocío University Hospital, Endocrinology, Sevilla, Spain; 2Virgen del Rocío University Hospital, Nuclear Medicine, Sevilla, Spain
Background: The indication of ablation with I131 in low-risk DTC is controversial. The exact dose needed for thyroid remnant ablation is still a matter of debate in low-risk DTC patients. However, low dose has been found to be equally effective as high dose in terms of recurrence rate in recent studies. Taking this into account the current trend is to administer lower doses, although some studies describe a higher rate of retreatment.
Aims: 1. To examine whether there is difference in the response to treatment with 30 vs >30 mCi dose in patients with low-risk DTC.
2. To study if there are predictor variables for needing a second I131 dose in low-risk DTC
Material and method: This is a cohort study of pre-ablation low-risk DTC patients undergoing treatment with 30 mCi vs > 30 mCi of 131I between 2017 and 2020. Tumor variables, biochemical characteristics, response after ablation (at one year), and need for a second 131I dose were analyzed. Qualitative variables are expressed as n(%) and quantitative variables as median [IQR]. We used Chi-square and the Kruskal-Wallis test for independent samples to compare both groups.
Results: Both groups are comparable. There were no differences in the type of response and the need for a second dose between groups. However, pre-ablation Tg, stimulated Tg, and pre-ablation AbTg were significantly higher in patients requiring a second dose (P 0.01, P 0.001, and P 0.04, respectively).
| 30 mCi | >30 mCi | ||
| Median dose (mCi) | 30[30-30] | 80[80-80] | |
| N | 74 | 62 | |
| Women | 64(86.5%) | 50(80.6%) | |
| Age (years) | 55[42-64] | 54[45-66] | |
| Tumor type | Papillary | 73(98.6%) | 58(93.5%) |
| Follicular | 1(1.4%) | 3(4.6%) | |
| Tumor size | T1 | 34(46%) | 23(37%) |
| T2 | 33(44.5%) | 30(48.3%) | |
| Excellent response | 53(71.7%) | 48(77.4%) | |
| Second dose | 16(21.6%) | 9(14.5%) |
| Second dose | pre-ablation Tg (ng/ml) | stimulated Tg (ng/ml) | pre-ablation AbTg (UI/ml) |
| No | 0.20 [0.04-0.79] | 0.55 [0.06-1.70] | 10[10-11.7] |
| Yes | 0.44[0.22-1.54] | 2.30[0.79-5.53] | 10.35[10-196] |
Conclusions: In low-risk DTC patients, the response to treatment with 30 mCi is like that with higher doses. High pre-ablation Tg and AbTg should guide us to use higher doses of I131.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more